RxDoctor Payments Data

Nirali Patel, MD

Internal Medicine · Fayetteville, NCNPI 1346772027

Payments from drug & device makers

$431in general payments, 2019–2025

Across 23 payments — averaging $18.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$106
  • AbbVie$81
  • GSK$37
  • Eisai Inc.$36
  • Braeburn Inc.$33
  • Astellas Pharma US Inc$27
  • plus $111 from 6 others

What the payments were for

  • Food & beverage$431100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)6$106
AbbVie4$81
GSK2$37
Eisai Inc.2$36
Braeburn Inc.2$33
Astellas Pharma US Inc1$27
Johnson & Johnson1$27
Novo Nordisk1$23
Indivior Inc.1$22
Medtronic1$19
Bardy Diagnostics, Inc.1$15
Organon1$6

How this compares

$431 in reported general payments places this provider in the 60th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$2,417
Medicare patients
53
Services billed
180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$39,287
TradjentaLinagliptin42$33,739
SublocadeBuprenorphine15$30,614
FarxigaDapagliflozin Propanediol31$29,713
OzempicSemaglutide22$28,839
JardianceEmpagliflozin26$16,529
JanuviaSitagliptin Phosphate17$10,684
ShingrixVaricella-Zoster Ge/As01b/Pf43$9,606
AbrysvoRsv Vacc, Pref A And Pref B/Pf26$8,268
JanumetSitagliptin Phos/Metformin Hcl11$7,330
Breo ElliptaFluticasone/Vilanterol13$5,211
CreonLipase/Protease/Amylase12$4,410
Atorvastatin Calcium208$2,432
Boostrix TdapDiphth,pertuss(Acell),tet Vac34$2,336
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl22$1,220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Indivior Inc.Sublocade$22$30,61415 claims
AstraZenecaFarxiga$106$29,71331 claims
Novo NordiskOzempic$23$28,83922 claims
GSKShingrix, Breo Ellipta$37$14,81756 claims
AbbVieCreon$81$4,41012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →